Trimebutine

Summary

Trimebutine (CHEMBL190044) is a phase-3 clinical-stage small molecule (ATC A03AA05); indicated across 2 conditions including irritable bowel syndrome.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: A03AA05
• Indications: 2 conditions
• Clinical trials: 5
• Chemistry: 387.5 Da · C22H29NO5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL190044
Name	Trimebutine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	5573
ATC	A03AA05
Molecular formula	C22H29NO5
Molecular weight	387.5
InChIKey	LORDFXWUHHSAQU-UHFFFAOYSA-N

SMILES: CCC(COC(=O)C1=CC(=C(C(=C1)OC)OC)OC)(C2=CC=CC=C2)N(C)C

IUPAC name: [2-(dimethylamino)-2-phenylbutyl] 3,4,5-trimethoxybenzoate

Also known as: Trimebutina, Trimebutine, TRIMEBUTINE, Trimebutine maleate, TRIMEBUTINE MALEATE, trimebutine

Parent form; salt/anhydrous children: CHEMBL1325297

Patent coverage: 881 distinct patent families (2,955 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 13 (assay-derived). Sample: Neuronal acetylcholine receptor subunit alpha-4, Alpha-2B adrenergic receptor, Muscarinic acetylcholine receptor M2, Sodium-dependent serotonin transporter, Mu-type opioid receptor, Delta-type opioid receptor, Kappa-type opioid receptor, Sodium-dependent dopamine transporter, Voltage-gated inwardly rectifying potassium channel KCNH2, Adenosine receptor A3, 3’,5’-cyclic-AMP phosphodiesterase 4D, Nuclear receptor subfamily 1 group I member 2, Voltage-dependent L-type calcium channel subunit alpha-1C.

Bioactivity

ChEMBL activities: 7 potent at pChembl ≥ 5 of 14 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
OPRK1	6.72	AC50	190	nM	CHEMBL_ACT_25129648
OPRM1	6.7	AC50	200	nM	CHEMBL_ACT_25147057
SLC6A4	6.06	AC50	870	nM	CHEMBL_ACT_25150565
CHRM2	5.92	AC50	1200	nM	CHEMBL_ACT_25213960
KCNH2	5.77	AC50	1700	nM	CHEMBL_ACT_25118207
OPRD1	5.4	AC50	4000	nM	CHEMBL_ACT_25154305
NR1I2	5.34	AC50	4600	nM	CHEMBL_ACT_25224453

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
irritable bowel syndrome	2	MONDO:0005052	EFO:0000555

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE4	2
PHASE2/PHASE3	1
PHASE1/PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02986685	PHASE4	WITHDRAWN	Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole
NCT04403087	PHASE4	COMPLETED	Trimebutine on the Development of Adverse Events Related to the Helicobacter Pylori Eradication Medications
NCT03359499	PHASE2/PHASE3	COMPLETED	Impact of Bacillus Clausii Administration on Irritable Bowel Syndrome Patients
NCT06268964	PHASE1/PHASE2	RECRUITING	Exploring Treatments for Children’s Abdominal Pain: Comparing Trimebutine and Probiotics
NCT03036111	Not specified	SUSPENDED	Effect of Topical Trimebutine on Pain After Hemorrhoidectomy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).